Utama › Sindrom Sjogren › North Carolina
Kajian klinikal Sindrom Sjogren di North Carolina
6 kajian untuk Sindrom Sjogren sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- On Site Clinical Solutions Llc, Charlotte
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07621809Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
- Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT07404865AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Charlotte, Charlotte
- Artiva Investigational Site Statesville, Statesville
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT06991114A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- Arthritis and Osteoporosis Consultants of The Carolinas - Charlotte - 1918 Randolph Rd, Charlotte
- Duke Early Phase Clinical Research Unit - PPDS, Durham
- Onsite Clinical Solutions, LLC - Salisbury, Salisbury
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Apr 2026 · NCT06747949Maternal Autoimmune Disease Research Alliance (MADRA) Registry
- Duke University, Durham
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Semua umur · Wanita · Dikemas kini 8 Jan 2026 · NCT03276923The Myelin Disorders Biorepository Project
- Atrium Health Wake Forest Baptist, Winston-Salem
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 23 Okt 2025 · NCT03047369Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.